Technology relates to a Docosahexaenoic acid (DHA) in its free fatty acid form which is directly compressible and a process of isolation from oils, and fats of natural origin having Docosahexaenoic acid attached to triglycerides. The DHA produced by this method is free from triglycerides, has purity of more than 90 percent, and the DHA free in its free fatty acid powder form offers excellent bioavailability and stability at room temperature.

For more details about technology: Click here

Invention relates to a novel process of isolation and characterisation of nutraceutical ingredients from moringa olefira. The proposed process involves: separation of oil & cake from the seed powder by cold expression, followed by extraction, freezing, evaporation by spray drying or freeze drying. The products isolated by using this process can be used against diabetes, and wound healing among other nutraceutical applications.

Technology relates to a smartphone based urine analysis system that can measure 10 parameters in urine. Urinalysis can diagnose and help manage up to 25 medical conditions, including diabetes, kidney and liver problems and common infections like UTIs. The system consists of an app that reads color changes in strips dipped in the test sample, and a peripheral kit to make this happen reliably.

For more details about technology: Click here

Technology relates to an Intralock Intravenous Cannula solving the problems with the existing intravenous cannula products using a concept of non-return valve, instead of using a hard plastic as the cannula valve. Using this system clotting of blood and oozing of blood is prevented.

For more details about technology: Click here

Invention relates to novel bioactive lipids, which are obtained from ethylene glycol by trans esterification of fatty acid esters with ethylene glycol. The novel lipid products obtained from ethylene glycol are bioactive and can be used as anti-bacterial, anti-fungal, anti-inflammatory, wound healing, anti-obesity and as anti-cancer agents and can also be used as non-ionic surfactant.

Invention relates to process for preparing optically pure milnacipran and their pharmaceutically acceptable salts using D/L- mandelic acid as resolving agents. The process is simple and economical as it uses low cost commercially available resolving agents and industrially scalable.

For more details about technology: Click here